Aligos Therapeutics, Inc. (ALGS)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 965K | 741K | 169K | 2.8M |
| Operating Income | -18.6M | -28.4M | -21.8M | -26.9M |
| Net Income | -15.9M | -31.5M | -19.9M | -23.0M |
| Diluted EPS | $-1.53 | $-3.04 | $-1.91 | $-2.21 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 13.9M | 15.5M | 3.9M | 2.2M |
| Operating Income | -97.6M | -88.1M | -89.2M | -88.0M |
| Net Income | -96.0M | -87.7M | -131.2M | -24.2M |
| Diluted EPS | $-56.25 | $-34.20 | $-20.94 | $-2.45 |